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EPID dosimetry – Characteristics of a 
commercial software: EPIgray
Kate Ricketts, Clara Navarro, Abiodun Adeyemi (RBH) 
• Aims and current in vivo dosimetry
• Introduction to EPIgray
• Software commissioning and evaluation results:
• Phantom measurements
• Patients
Outline
Towards Safer Radiotherapy report
“All centres must have protocols for in vivo dosimetry”
• Aim: To implement and evaluate a new in vivo dosimetry system for 
use at RBH
Project Aims
Current limitations - Diodes
• Diodes Surface dose only
• Sensitive to diode positioning
• One point per field
• Time consuming
• Dose shielding effect
• Not suitable for VMAT
Profile #1 (6x6 sq field)
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EPIgray dose 
reconstruction through 
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cf RTplan
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dose
Introduction to EPIgray
•Calibrate EPIDs for dosimetry (so far used for imaging only)
•Measure EPID and beam data for EPIgray library
(chamber at EPID level vs EPID signal, finite TMR measurements, 
planning data – PDDs, beam profiles – open / wedged)
•Connectivity: between EPIgray, Eclipse, iViewGT and Mosaic 
•Workflow (radiographer / physics input)
•Software evaluation – worked 
closely with DOSIsoft
Commissioning work
• Accuracy: field size effects, PDDs, wedges
• Compared with TPS values, (future: to compare with measurement)
• Linearity with dose and reproducibility
• IMRT and VMAT capabilities
Software Evaluation
Sensitivity to errors:
•Can SSD changes be picked up?
•Can patient thickness changes be identified?
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Good agreement: ΔD (EPIgray vs TPS) of 6 MV: -0.5% (0.4 cGy) 
10 MV: -0.3% (0.3 cGy) on cax.
Off axis +/- 4 cm: max difference -2.4% and -3% for 6 and 10 MV 
Beam Profiles
100 MU, 20 cm solid water, 20 x 20 cm field, 90 cm SSD
Percentage depth doses
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Wedged fields
Poorer agreement: ΔD (EPIgray vs TPS) of 6 MV: -4.5% 
10 MV: -1.9% on cax.
Off axis +/- 4 cm: thick end -3.2% (-1.1%) and thin end -8.5% (-3.9%) for 6 MV (10 MV) 
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Linearity
•Tested 5 MU – 500 MU at 6 MV and 
10 MV
•Pink line: EPIgray = Eclipse dose
•All point lie on pink line
•Linear response of EPID
Reproducibility
•Tested for images taken on same day
•Day-to-day reproducibility yet to be tested
6 MV 10 MV
CAX
(5 cm and 10 cm deep) 1.15% (0.01 Gy) 1.5% (0.01 Gy) 
± 2 cm laterally off-axis 
(10 cm deep) All results within 
2.0%
2.5% (0.02 Gy)
97%
98%
99%
100%
101%
102%
103%
80% 90% 100% 110% 120%
SSD factor (treated error SSD / intended 90cm SSD) 
(%)
R
e
c
o
n
s
tr
u
c
te
d
 d
o
s
e
 /
 e
x
p
e
c
te
d
 
d
o
s
e
 a
t 
9
0
c
m
 S
S
D
 (
%
) 6MV
10MV
•10% difference in FSD gives ~ 2% difference in reconstructed 
dose
•Require additional FSD check
Sensitivity to FSD changes
Not sensitive to 
FSD error
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Percentage change in patient separation
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•10% change in patient separation seen as ~ 10% change 
in reconstructed dose
Sensitivity to patient thickness
Sensitive to patient 
thickness change
Treatment Delivery Errors Patient Changes
• MU errors
• Patient set-up
• MLC/ wedge errors
• Patient thickness
• Anatomical changes – bowel 
gas, respiration, bladder filling
Limitations: not sensitive to changes in SSD
Detectable errors
Patient trial results
Breast FinF
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3D conformal 38 fields
All fails = chest wall patients Fails = bowel gas
Mean= -0.2% ± 3.2 % (1σ)
[-0.4 cGy ± 4.5 cGy]
Max abs. dose diff = -12 cGy
Breast 18 fields 3D conformal 38 fields
Mean= -4.3% ± 4.8 % (1σ)
[-1.5 cGy ± 1.8 cGy]
Excluding rectum (brain only)
Mean= -3.1% ± 2.4 % (1σ)
IMRT Pelvis 44 fields 6 patients
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IMRT pelvis 44 fields
HN IMRT 33 fields 3 patients 5 fractions
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
Eclipse dose (Gy)
E
p
ig
ra
y
 d
o
s
e
 (
G
y
)
•Point not in open field
•Air gaps changeable
IMRT head and neck 33 fields
•EPIgray Systematically lower 
than TPS dose
Mean= -5.2% ± 3.3 % (1σ)
[-2.5 cGy ± 1.5 cGy]
Fail Point under MLC for most segments
IMRT Head and Neck 34 fields
Mean= -8.9% ± 17 % (1σ)
[-2.7 cGy ± 3.5 cGy]
IMRT Pelvis 44 fields
Max absolute dose difference = -17 cGy
Point dose comparison not suitable for IMRT 
dose verification
Tolerances: 
Pass = gamma index < 1
Results:
IMRT pelvis: 52 points Avg: 0.75 std: 0.5
IMRT H&N: 34 points Avg:0.6  std:0.3
Exploring use of local gamma index – new feature of EPIgray
Breast FinF plans: 5% (7% chest wall)
Conformal plan: 5% brain 7% rectum 
IMRT pelvis: gamma index < 1 (5%/5mm)
IMRT head and neck gamma index < 1 (5%/5mm)
Initial tolerances based on patient trial – to be reviewed 
Recommendations
• Dose reconstruction point should lie:
• < 2cm from cax 
• > 2 cm from field edge
• not in low or high density region
• Not in region where beam path traverses inhomogeneity / rapidly 
changing body contour
• Isocentre taken as default point for majority of fields
• EPIgray not sensitive to FSD error: require additional FSD check
• Commissioning easy
• EPIgray tests reveal good agreement with TPS dose on cax
• linearity, reproducibility, patient thickness, FSD changes
• Further work to improve performance of wedge modelling 
• Patient trial needed to set initial tolerances
Conclusions
Thank you
